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ABSTRACT
Previous Epstein-Barr virus (EBV) prophylactic vaccines based on the major 
surface glycoprotein gp350/220 as an immunogen have failed to block viral infection 
in humans, suggesting a need to target other viral envelope glycoproteins. In 
this study, we reasoned that incorporating gH/gL or gB, critical glycoproteins for 
viral fusion and entry, on the surface of a virus-like particle (VLP) would be more 
immunogenic than gp350/220 for generating effective neutralizing antibodies to 
prevent viral infection of both epithelial and B cell lines. To boost the humoral 
response and trigger cell-mediated immunity, EBV nuclear antigen 1 (EBNA1) and 
latent membrane protein 2 (LMP2), intracellular latency proteins expressed in all 
EBV-infected cells, were also included as critical components of the polyvalent 
EBV VLP. gH/gL-EBNA1 and gB-LMP2 VLPs were efficiently produced in Chinese 
hamster ovary cells, an FDA-approved vehicle for mass-production of biologics. 
Immunization with gH/gL-EBNA1 and gB-LMP2 VLPs without adjuvant generated 
both high neutralizing antibody titers in vitro and EBV-specific T-cell responses in 
BALB/c mice. These data demonstrate that EBV glycoprotein(s)-based VLPs have 
excellent immunogenicity, and represent a potentially safe vaccine that will be 
invaluable not only in preventing EBV infection, but importantly, in preventing and 
treating the 200,000 cases of EBV-associated cancers that occur globally every year.
INTRODUCTION
Infection with Epstein-Barr virus (EBV), an 
oncogenic gamma-herpesvirus, is associated with the 
development of lymphoproliferative disorders and 
over 200,000 cancer cases worldwide every year [1, 
2]. Preclinical and clinical studies of EBV candidate 
vaccines have demonstrated that boosting the immune 
response against EBV can limit viral infection and protect 
both animals and humans from developing EBV-related 
diseases [3-6]. Yet EBV vaccine development has met 
several challenges, including: the potential oncogenic 
effects of introducing EBV DNA/RNA using virions; 
limited production and release of the virus particles to 
be used as vaccine; and propagation of many vaccine 
candidates in transformed human cell lines, limiting the 
ability to meet the stringent FDA safety guidelines. For 
example, recent phase I clinical trials of recombinant 
modified vaccinia Ankara (MVA) vector encoding EBV 
nuclear antigen 1 (EBNA1) and latent membrane protein 
2 (LMP2) as a vaccine candidate elicited a robust EBV-
specific CD4+ and CD8+ T-cell response in humans [6-8]. 
However, the use of MVA to deliver these two important 
EBV antigens, known for their oncogenic potential, may 
pose major health risks, such as integrating oncogenic 
DNA in an undesired location of the host genome, and 
potentially causing unchecked cell growth, particularly 
in immunosuppressed individuals [9, 10]. There is also a 
risk of vaccine tolerance, since the proteins are constantly 
produced in vivo.
Another major limitation of vaccines currently in 
pre-clinical and clinical trials is that none of the vaccines 
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has created sterile immunity (i.e., complete blockage of 
viral infection), perhaps because most of the strategies 
only target one arm of the immune system, either humoral 
(e.g., major immunodominant EBV surface glycoprotein 
gp350/220, prophylactic vaccine) [2, 11] or cell-mediated 
(e.g., MVA-EBNA1-LMP2, therapeutic vaccine). Even in 
cases where both arms of the immune system have been 
targeted in a single vaccine, such as with the use of EBV 
DNA packaging mutants [12, 13], the vaccine candidates 
were met with safety concerns.
Virus-like particles (VLPs) overcome many of these 
challenges. VLPs lack the viral genome and typically 
assemble from one or more viral structural proteins, 
forming repetitive arrays that resemble a natural virus [14]. 
Importantly, VLPs are known for strong immunogenicity 
and safety in all populations, regardless of immune 
status [15]. The recent success of subunit-based VLP 
vaccines targeting other oncogenic viruses (e.g., human 
papillomavirus and hepatitis B virus [16, 17]), suggests a 
similar strategy could be safe and effective for EBV. Our 
Newcastle disease virus-like particle (ND VLP) platform 
consists of expression vectors encoding recombinant EBV 
genes of interest and key NDV structural proteins, which 
are co-transfected into mammalian host cells for assembly 
and production of Epstein-Barr VLPs (EB VLPs) 
containing the target proteins [18-20]. Notably, ND VLPs 
provide a platform for the inclusion of multiple select viral 
surface glycoproteins and intracellular T-cell antigens to 
generate a polyvalent vaccine, which could stimulate both 
humoral and cell-mediated immune responses for effective 
EBV prevention and control.
EBV membrane glycoproteins, which are critical for 
viral entry and infection of host epithelial and B cells [21, 
22], provide attractive humoral immune response targets 
for inclusion in a prophylactic EBV vaccine. In EBV 
infection, the attachment surface glycoprotein gp350/220 
makes first contact with host B-cell receptors CD21 and 
CD35 [23-26], and subsequently triggers endocytosis of 
the virions [27]. Fusion between the viral envelope and 
host cellular membrane receptors is the next required step 
in the entry of all human herpesviruses [21]; for EBV, the 
necessary viral envelope glycoproteins include gH and gL 
[28-30], gp42 [31], and gB [32]. Importantly, co-expression 
of gH and gL is required for gL transport to the cell surface, 
and formation of a stable cell surface complex of gH/gL 
[33]. Together, these glycoproteins mediate EBV entry into 
both epithelial and B cells, and thus they facilitate infection 
and confer host cell specificity. Fusion with epithelial cells 
is facilitated by both gH/gL and gB [32-34], while B-cell 
tropism is defined by gH/gL and gp42 [35].
Although neutralizing antibodies (nAbs) directed 
to EBV envelope glycoproteins are present in humans, 
prevent neonatal infection, and are generated in response 
to EBV infection in humans, or to immunization with 
virus glycoproteins in humans and other animals [3, 36, 
37], persistent EBV infection and evidence of limited 
immune selection of viral antigenic variants indicate that 
in vivo neutralization of EBV infection is suboptimal. 
In support of these observations, in four independent 
phase I/II clinical trials, vaccination with vector 
constructs expressing gp350/220 or with the purified 
recombinant non-splicing variant, gp350, soluble protein 
did not prevent infection, although acute infectious 
mononucleosis (AIM) was reduced in young adults [3, 
4, 38, 39]. Importantly, primary B-cells can be infected 
with recombinant EBV lacking gp350/220, suggesting 
that additional viral ligands mediating EBV infection 
in the absence of gp350/220 may exist [40]. These 
observations indicate that using gp350/220 as the only 
immunogen to target viral neutralization is not optimal 
and may account for the variable success of this protein 
in EBV vaccine development [3-5, 11, 38]. This evidence 
drove our use of other critical EBV glycoproteins (gH/gL 
and gB) as alternative vaccine targets for generating an 
effective antibody response in immunized mice and in our 
development of a polyvalent vaccine.
Much evidence establishes EBV intracellular 
latency proteins EBNA1 and LMP2 as attractive targets 
for stimulation of a cell-mediated immune response in 
a therapeutic EBV vaccine candidate [6-8, 41-46]. Both 
are expressed in all EBV-infected cells, including EBV-
related tumors [1]. EBNA1 and LMP2-specific CD4+ and 
CD8+ T cells are frequently detected in EBV-infected 
individuals [43, 47, 48], and both T-cell subsets can be 
effective in controlling growth of EBV-immortalized 
epithelial or B cells [8, 39, 44, 45]. Furthermore, 
immunosuppression of EBV-positive individuals typically 
leads to EBV-associated lymphomas and post-transplant 
lymphoproliferative disorders (PTLDs) [49]. Adoptive 
transfer of EBV-specific T cells can induce remission 
in transplant patients [50, 51], suggesting that T cell-
mediated responses are effective in controlling persistent 
EBV infection.
In this study, we provide evidence that subunit 
VLPs can incoporate EBV surface glycoproteins, package 
intracellular antigens, and that the VLPs can be stably 
produced in the Chinese hamster ovary (CHO) cell line. 
The polyvalent EB VLPs can stimulate both humoral and 
T cell-mediated immune responses in wild-type BALB/c 
mice. To our knowledge, these combinations have not yet 
been tested in pre-clinical or clinical trials as part of a 
prophylactic and therapeutic EBV vaccine candidate.
RESULTS
VLPs that incorporate gp350/220-F on the 
surface and package eGFP-NP intracellularly 
are stably produced in CHO cells
VLPs have typically been used to express only 
surface glycoproteins, for stimulation of the humoral 
immune response [14]. In addition, current production 
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of most VLPs requires repeated transient transfections of 
multiple plasmid components. This process is laborious, 
expensive, and results in varying yields of VLPs. As a 
proof of concept, we generated a novel polyvalent EBV 
vaccine that can package both surface glycoproteins and 
intracellular proteins, for stimulation of both humoral and 
cell-mediated immune responses, and is stably expressed 
in CHO cells following a single transfection.
To demonstrate that both surface glycoprotein(s) 
and intracellular proteins can be packaged in a VLP, we 
generated plasmids encoding genes to be incorporated as 
part of the EB VLP, surface glycoprotein (gp350/220) and 
enhanced green fluorescent protein (eGFP), a marker for 
intracellular expression. First, we synthesized chimeric 
sequences of EBV gp350/220 surface glycoprotein fused 
to the NDV fusion (F) protein transmembrane (TM)/
cytoplasmic (CT) domains (gp350/220-F; Figure 1A, 
top panel) and eGFP fused to NDV nucleocapsid protein 
(NP) (eGFP-NP; Figure 1A, bottom panel). To assemble 
and produce gp350/220-eGFP VLPs, equal amounts of 
pCAGGS-gp350/220-F and pCAGGS-eGFP-NP chimeras 
were co-transfected into CHO cells, together with 
pCAGGS-NDV matrix (M) protein (Figure 1B). pCI-puro 
was included in the transfection for the selection of stable 
cells.
To confirm successful transfection and intracellular 
expression of chimeric protein eGFP-NP, we used 
fluorescence microscopy to visualize expression of eGFP 
in CHO cells 48 hours post-transfection. Over 80% of cells 
transfected with pCAGGS plasmids expressing eGFP alone 
(control); eGFP-NP; or eGFP-NP, gp350/220-F, and M 
(i.e., gp350/220-eGFP VLPs) expressed eGFP-NP protein 
(Figure 1C). VLP-producing CHO cells were expanded and 
VLPs were purified as described [18, 20]. To demonstrate 
that CHO cells assembled and released gp350/220-eGFP 
VLPs, we confirmed expression of component proteins 
using immunoblot of purified gp350/220-eGFP VLPs and 
relevant controls (Figure 1D). Anti-eGFP detected eGFP 
and/or eGFP-NP chimeric proteins in lysates from B95-
8-eGFP cells, in CHO cells transfected with pCAGGS-
eGFP or pCAGGS-eGFP-NP (positive controls), as well as 
in purified gp350/220-eGFP VLPs (top panel to the left). 
Media alone, NDV lysate, CHO cells transfected with empty 
pCAGGS vector (negative controls), CHO cells transfected 
with pCAGGS-NP, and purified gp350/220 VLPs did not 
express eGFP. Anti-NDV, which recognizes NDV NP, 
detected NP and/or eGFP-NP in CHO cells transfected 
with pCAGGS-NP or pCAGGS-eGFP-NP, and in NDV 
lysate (positive controls), as well as in purified gp350/220-
eGFP and gp350/220 VLPs (which contain NP as a VLP 
constituent). Lysates from B95-8-eGFP cells, media 
alone, and CHO cells transfected with empty pCAGGS 
vector (negative controls), or CHO cells transfected with 
pCAGGS-eGFP did not express NP (bottom panel to the 
right). Anti-gp350/220 monoclonal antibody (mAb; 72A1) 
detected gp350/220 and/or gp350/220-F chimeric proteins 
in lysates from B95-8-eGFP cells as well as soluble 
gp350/220 (positive controls), and in purified gp350/220-
eGFP and gp350/220 VLPs. NDV lysate, media alone, 
and CHO cells transfected with empty pCAGGS vector 
(negative controls), CHO cells transfected with pCAGGS-
NP, pCAGGS-eGFP, or pCAGGS-eGFP-NP did not express 
gp350/220 (right panel). Thus, the purified gp350/220-
eGFP VLPs contained the appropriate gp350/220-F surface 
glycoprotein and eGFP-NP intracellular components. To 
confirm that the gp350/220-F chimeric protein expressed on 
the VLPs was functional, we tested for binding of purified 
VLPs to the gp350/220 cognate receptor, CD21. We 
incubated purified VLPs with Raji cells, known to express 
CD21, and used flow cytometry with anti-gp350/220 
(72A1) to detect bound VLPs (Figure 1E). Untreated 
Raji cells (negative control) demonstrated no gp350/220 
binding. Raji cells incubated with purified gp350/220 or 
gp350/220-eGFP VLPs showed gp350/220 bound to 90.5% 
and 97.5% of cells, respectively, similar to purified B95-8-
eGFP (positive control).
To generate a colony of stable VLP-producing 
cells, CHO cells transfected with pCAGGS-gp350/220-F, 
pCAGGS-eGFP-NP, pCAGGS-M and pCI-puro were 
selected with 10 µg/ml of puromycin 48 hours post-
transfection. Five colonies of stable cells were randomly 
selected, expanded, and sorted by flow cytometry using 
eGFP and anti-gp350/220 mAb 72A1. Sorted stable 
cells were expanded and VLPs were purified as above. 
Confocal microscopy analysis of the stable cells for eGFP 
expression, and immunoblot analysis of VLPs purified 
from stable cells, revealed that stable cells produced VLPs 
equivalent to those produced in the initial transfection, up 
to passage 10, without any remarkable loss in quantity of 
gp350/220 in purified VLPs (Figure 1F). These results 
confirm that the EBV VLP platform can be used to 
package both EBV intracellular and surface glycoproteins, 
and that VLPs can be stably produced in CHO cells 
following a single transfection step.
Construction, purification, and characterization 
of gp350/220-EBNA1, gH/gL-EBNA1, or gB-
LMP2 VLPs
Although the major EBV envelope glycoprotein 
gp350/220 has been proposed as a potential vaccine 
antigen, attempts to develop a potent gp350/220-based 
vaccine in the past four decades have had limited success 
[2, 11, 52]. We thus hypothesized that an alternate 
envelope glycoprotein, such as the complex gH/gL or gB, 
which are essential for EBV fusion and entry, would be 
a critical component for an effective antibody-mediated 
prophylactic vaccine. EBV-related malignancies such as 
Burkitt lymphoma, Hodgkin’s disease, and nasopharyngeal 
carcinoma typically express EBV nuclear antigen 
1 (EBNA1) and varying levels of latent membrane protein 
2 (LMP2) [1]. Thus, we reasoned that incorporating 
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EBNA1 or LMP2 into gp350/220, gH/gL or gB VLPs, 
respectively, would improve immunogenicity by targeting 
the cell-mediated arm of the immune system, in addition 
to the humoral arm targeted by the surface glycoprotein 
components.
To demonstrate the efficacy of packaging 
both viral surface glycoproteins (gp350/220 or gH/
gL) and an intracellular latency protein (EBNA1) 
inside a VLP, we used a similar strategy as above to 
generate both gp350/220-EBNA1 (Supplementary 
Figure S1) and gH/gL-EBNA1 VLPs (Figure 2). To 
construct the gH/gL-EBNA1 VLP, we synthesized 
chimeric sequences of: EBV gH ectodomain fused 
to the NDV F TM/CT domains (gH-F, Figure 2A); 
EBV gL ectodomain fused to NDV hemagglutinin-
neuraminidase (HN) protein TM/CT domains (gL-HN, 
Figure 2B); and EBV truncated (t) EBNA1 fused to 
full-length NDV NP (tEBNA1-NP, Figure 2C). Given 
that endogenously expressed full-length EBNA1 is 
protected from cytotoxic T lymphocyte recognition, 
making its recognition and presentation to MHC class I 
a challenge, we reasoned that to make an immunogenic 
vaccine, a truncation of EBNA1 would be necessary. 
In this truncation, the Gly-Ala region, known to impair 
presentation of cis-linked sequences (amino acids 
1-325) to MHC class I is deleted. The fragments were 
individually cloned into pCAGGS and cDNA fidelity 
was verified by sequencing.
To demonstrate that chimeric gH-F and gL-HN form 
gH/gL complexes at the surface of the transfected cells, 
similar to full length gH/gL or gH alone, we transfected 
CHO cells with the relevant pCAGGS plasmids. At 48 
hours post-transfection, cells were scraped, stained with 
anti-gH (E1D1) (Figure 2D) or anti-gH (CL59) (data 
not shown), and analyzed by flow cytometry. gH and/or 
gH/gL surface proteins were detected on CHO cells co-
transfected with full-length gH and gL or with chimeric 
gH-F and gL-HN, as well as CHO cells transfected with 
full-length gH only or the gH-F chimera. Untransfected 
CHO cells, or CHO cells transfected with empty pCAGGS 
Figure 1: Assembly and characterization of gp350/220-eGFP-NP VLPs. A. Schematic illustrations (not to scale) of gp350/220-
eGFP VLP plasmid constructs depicting the full length NDV-F, gp350/220 (wild type), and the gp350/220-F (chimeric) as well as the NDV-
NP, eGFP, and fusion of eGFP-NP cDNAs. B. A schematic workflow for the transfection of CHO cells with three required VLP components, 
NDV M, eGFP-NP, and gp350/220-F, resulting in gp350/220-eGFP VLPs. C. Fluorescence microscopy comparing eGFP expression in 
CHO cells transfected with pCAGGS-eGFP, pCAGGS-eGFP-NP, and the three VLP components in comparison to untransfected CHO cells, 
showing that all three conditions result in eGFP expression at nearly equal levels. (Continued )
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plasmid, served as negative controls. Detection of gL alone 
was not performed due to lack of commercial antibody.
To assemble and produce the gH/gL-EBNA1 VLPs, 
equal amounts of cDNAs (8 µg/T-175 flask) of pCAGGS-
gH-F, pCAGGS-gL-HN, and pCAGGS-tEBNA1-NP 
chimeras were co-transfected into CHO cells, together 
with pCAGGS-M (Figure 2E). VLPs were purified as 
previously described [18, 20]. To confirm the production 
of gH/gL, tEBNA1, M, and NP VLP components, 
purified gH/gL-EBNA1 VLPs were analyzed for protein 
composition and molecular weight using immunoblot 
(Figure 2F–2G) and silver stain (Figure 2H). Anti-
EBNA1 directed to the DNA binding domain detected 
tEBNA1 and/or tEBNA1-NP chimeric protein in CHO 
cells transfected with pCAGGS-EBNA1 full-length or 
pCAGGS-tEBNA1-NP (positive controls), as well as 
purified gH/gL-EBNA1 VLPs, but not in untransfected 
CHO cells (negative control), purified gp350/220 VLPs, 
or CHO cells transfected with pCAGGS-LMP2. Anti-
NDV detected NP and/or tEBNA1-NP chimeric protein 
in purified gH/gL and gH/gL-EBNA1 VLPs, as well as 
NDV lysate (positive control), but not in untransfected 
CHO cells (negative control), or CHO cells transfected 
with pCAGGS-EBNA1. As an effective antibody against 
gH/gL has not been optimized for immunoblotting, silver 
stain was used to detect VLP component proteins as well 
as to assess VLP purity. NDV lysate was used as a positive 
control; BSA was used for quantification of protein. Bands 
for gH/gL-EBNA1 VLP component proteins of predicted 
sizes were detected for chimeric tEBNA1-NP (109 Kda), 
gH/gL (130 Kda), gH-F (85 Kda), NDV NP (53 Kda), 
NDV M (40 Kda), and gL-HN (25 Kda). Even though 
Figure 1: (Continued ) Assembly and characterization of gp350/220-eGFP-NP VLPs. D. VLP immunoblots confirming eGFP 
(top panel to the left), NDV (bottom panel to the left), and gp350/220 (panel to the right) expression. The anti-eGFP blot detected eGFP 
protein in cells transfected with various eGFP plasmids, EBV eGFP, as well as in VLPs containing eGFP. The anti-NDV (a gift of Dr. T. 
Morrison, University of Massachusetts Medical School), detects expression of the eGFP-NP fusion protein as well as NP. Finally, the anti-
gp350/220 blot shows expression of both gp350 and 220 in both VLPs. E. To confirm that the VLPs bound to the surface receptor CD21, 
purified EBV and gp350/220 VLPs were incubated with Raji cells (expressing CD21), stained with anti-gp350/220, and FACs analysis was 
performed to see if the VLPs would bind to the receptor and how well they bound in comparison to eGFP-EBV. At least ~90% of the cells 
fluoresced green when either virus or VLP was bound. F. Confocal microcopy confirmed that CHO cells transfected with the three VLP 
components stably expressed both gp350/220 (on the surface of the cells, red color) and NP-eGFP (predominantly in the nucleus, green 
color). DAPI was used to stain the nucleus. Immunoblot of purified VLPs also detected expression of gp350/220 after passaging CHO 10 
times, indicating that the gp350/220-eGFP VLPs can be stably produced in CHO cells.
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E1D1 was recently shown to detect the gH/gL complex 
in immunoblot [53], in our hands, this antibody did not 
detect gH/gL in purified EBV, in cells transfected with gH/
gL, or in VLPs in both non-reducing and reducing buffers. 
Further review of the literature did not identify any other 
previously published article detecting gH/gL with E1D1 
Figure 2: Construction, assembly, and characterization of gH/gL-EBNA1 VLPs. Schematic illustrations (not to scale) of 
A. EBV gH-NDV F, B. EBV gL-NDV HN, and C. EBV tEBNA1-NDV NP chimera plasmids. D. pCAGGS-cDNAs of the two chimeras 
and NDV Matrix were co-transfected into CHO cells for VLP production as illustrated. E. Flow cytometry for surface expression of gH 
and gH/gL on 106 CHO cells transfected with 1µg of (clockwise from top left): empty pCAGGS vector (neg. control); pCAGGS-gH-full-
length (WT) + gL-WT (pos. control); pCAGGS-gH-F + gL-HN chimeras; gH-F chimera; gH-WT; no transfection (CHO). SSC, side scatter; 
Anti-gH/gL mAb E1D1 binds gH alone or gH/gL complex (a gift of L. Hutt-Fletcher Louisiana State University, Shreveport). F. Purified 
gH/gL-EBNA1 VLPs and transfected cells were lysed and analyzed by immunoblot with mAb anti-DNA binding domain EBNA1 (a gift 
of F. Grässer, Institut für Virologie, Germany) to detect EBNA1. G. Sera from mice immunized with UV-KSHV was used to detect gH. 
Polyclonal anti-NDV was used to detect NP proteins (a gift of Dr. T. Morrison, University of Massachusetts Medical School, Worcester, 
Polyclonal anti-NDV MA), and anti-mouse sera from mice immunized with UV-inactivated EBV, as indicated (top panel). Anti-EBNA1: 
un-transfected CHO cells, purified gp350/220 VLP, and CHO cells transfected with LMP2 were neg. controls; CHO cells transfected with 
EBNA1-WT or NP-tEBNA1 chimera were pos. controls. Anti-NDV: un-transfected CHO cells and CHO cells transfected with EBNA1-WT 
were neg. controls; NDV was pos. control. H. Purity of EBV gH/gL-EBNA1 VLPs was determined by Silver stain, and VLP component 
proteins of predicted sizes were detected as indicated; NDV was pos. control, BSA was used for quantification.
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in immunoblot, a fact confirmed by Dr. L Hutt-Fletcher 
(Louisiana State University Health Sciences Center, 
Shreveport, LA).
Following the success of producing VLPs that 
express both surface glycoprotein and intracellular protein, 
we developed another VLP packaging EBV glycoprotein, 
gB, with full length LMP2. LMP2 is recognized by T 
cells and is immunogenic in the control of post-transplant 
lymphoproliferative diseases. We reasoned that it would 
be an excellent vaccine component when combined with 
gB, which was recently shown to also play an integral role 
in EBV entry [32]. To construct the gB-LMP2 VLP, we 
synthesized chimeric sequences of: gB ectodomain fused 
to the NDV F TM/CT domains (gB-F, Figure 3A) and full-
length LMP2 fused to NDV NP (LMP2-NP, Figure 3B). 
The fragments were individually cloned into pCAGGS 
and sequence fidelity was verified. To confirm surface 
expression of gB, we used flow cytometry with anti-gB 
(CL55). CHO cells transfected with the pCAGGS-gB-F 
chimera expressed gB similar to cells transfected with 
pCAGGS-gB (full length) and His-tagged gB (positive 
controls), while cells transfected with empty pCAGGS 
vector (negative control) did not express gB (Figure 3C).
To assemble and produce the gB-LMP2 VLPs, we 
co-transfected equal amounts of pCAGGS-gB-F, and 
pCAGGS-LMP2-NP chimeras into 40 T175 flasks seeded 
with CHO cells, together with pCAGGS-M (Figure 3D). 
Supernatant was collected from transfected cells from 
24-96 h post-transfection and VLPs were purified as 
previously described [18, 20]. To confirm the production 
of gB, LMP2, and NP VLP components, purified gB-
LMP2 VLPs were analyzed for protein composition and 
molecular weight using immunoblot (Figure 3E–3F) and 
silver stain (Figure 3G). Anti-gB (CL55, C-terminal) 
detected gB protein in CHO cells transfected with 
pCAGGS-gB (full length), pCAGGS-gB-His (positive 
controls), and in purified gB-LMP2 VLPs but not in 
NDV lysate, untransfected CHO cells (negative controls), 
or in purified gp350/220 or gp350/220-EBNA1 VLPs 
(Figure 3E, upper. Anti-gB (BA23, N-terminal) detected 
gB protein in CHO cells transfected with pCAGGS-
gB (full length) and pCAGGS-gB-His, but not in NDV 
lysate, untransfected CHO cells, or purified gB-LMP2 
(confirms successful fusion of gB ectodomain-only in 
the chimera), gp350/220, or gp350/220-EBNA1 VLPs 
(Figure 3E, lower). Anti-LMP2 detected LMP2-NP in 
CHO cells transfected with pCAGGS-LMP2-NP (positive 
control) and in purified gB-LMP2 VLPs, but not in NDV 
lysate or untransfected CHO cells (negative controls), 
or purified gB-EBNA1 or gp350/220-EBNA1 VLPs 
(Figure 3F, upper). Anti-NDV detected NP and relevant 
NP chimeras, in NDV lysate (positive control) and in 
gp350/220, gB-LMP2, and gp350/220-eGFP VLPs, but 
not in untransfected CHO cells (negative control) or CHO 
cells transfected with pCAGGS-gB or pCAGGS-gB-His 
(Figure 3F, lower). Silver stain was used to detect VLP 
component proteins as well as to assess VLP purity; NDV 
lysate was used as a positive control and BSA was used 
for quantification of protein. Bands for gB-LMP2 VLP 
component proteins of predicted sizes were detected for 
gB (100 Kda), chimeric LMP2-NP (80 Kda), NDV NP (53 
Kda), and NDV M (40 Kda) (Figure 3G).
VLPs stimulate both IgG-specific antibody and 
EBNA1- and LMP2-specific T-cell responses in 
immunized BALB/c mice
To test the efficacy of individual EB VLPs to 
generate antibodies and induce T-cell responses, nine 
groups (n=5/treatment) of 6–8-week-old female BALB/c 
mice were immunized intraperitoneally three times (Day 0, 
29, 54) with 10 μg of purified gH/gL-EBNA1 VLPs, gB-
LMP2 VLPs, or gp350/220 VLPs in 0.5ml of TNE buffer 
(100 mM Tris; 2.0 M NaCl; 10 mM EDTA; ~10% sucrose; 
pH 7.4). Purified UV-inactivated EBV (10 μg) was used 
to immunize mice as positive control; TNE buffer served 
as negative control. To test whether there are additive or 
synergistic effects of using two or more immunogens in 
the vaccine, we immunized groups of 5 mice with two 
or three individual VLPs (10 μg each of: gH/gL-EBNA1 
and gB-LMP2; gH/gL-EBNA1 and gp350/220; gB-
LMP2 and gp350/220; or gH/gL-EBNA1, gB-LMP2, and 
gp350/220). Mice were tail vein-bled to obtain serum at 
two and four weeks after primary immunization and again 
once after both secondary (Day 29) and tertiary (Day 54) 
boost immunizations (Figure 4A). Mice were sacrificed 
and terminal bleed was collected on Day 97.
To demonstrate the ability of VLPs to induce EBV 
subunit-specific antibody responses, we used enzyme 
linked immunosorbent assay (ELISA) to assess antibody 
titers against gH/gL, gB, gp350/220, and UV-inactivated 
EBV (positive control) in collected sera. First, lysates 
from lytically induced AGS-EBV-eGFP cells, which 
express all viral glycoproteins, were used as binding 
targets. Sera collected at Days 14, 18, 33, 46, 68, and 97 
(terminal bleed) were used to determine the presence of 
IgG-specific antibodies (Figure 4B). All VLP-immunized 
mice generated EBV-glycoprotein-specific IgG antibody 
responses that significantly increased following primary 
and secondary boost immunizations, compared to TNE 
(negative control). The increase in EBV-specific antibody 
response peaked at Day 68 for all VLP-immunized mice, 
similar to UV-inactivated EBV-immunized mice (positive 
control). Similar slope patterns were observed in the 
mice immunized with all VLPs (gp350/220, gB-LMP2, 
and gH/gL-EBNA1) compared to UV-inactivated EBV. 
gp350/220 VLP-immunized mice generated the highest 
amount of IgG-specific antibodies, compared to mice 
immunized with gB-LMP2 VLPs or gH/gL-EBNA1 
VLPs. To reduce non-specific background and to compare 
specific EBV glycoprotein gp350/220 IgG antibody 
titers in the sera of mice immunized with UV-inactivated 
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EBV, we used gp350 soluble proteins as binding targets 
for ELISA (Supplementary Figure S2). There are no 
commercially available purified gB or gH/gL proteins to 
allow us characterize antibody specificity to gB and gH/
gL. Individual EBV glycoprotein-specific antibodies were 
detected in all immunized mice, and again UV-inactivated 
Figure 3: Construction, assembly, and characterization of gB-LMP2 VLPs. Schematic illustrations (not to scale) of A. EBV 
gB-NDV F and B. EBV LMP2-NDV NP chimera plasmids. C. Flow cytometry for surface expression of gB on 106 CHO cells transfected 
with 1 µg of (from left): empty pCAGGS vector (neg. control); pCAGGS-gB-full-length (WT); His-tagged gB (pos. control); and gB-F 
chimera. SSC, side scatter; anti-gB mAb CL55 (known to bind gB N-terminal. D. pCAGGS-cDNAs of the two chimeras and NDV Matrix 
were co-transfected into CHO cells for VLP production as illustrated. E-G. Purified gB-LMP2 VLPs and transfected cells were lysed 
and analyzed by immunoblot to detect gB, M, NP and LMP2 proteins. (E) mAb-CL55 (N-terminal) and BA23 (C-terminal). (F) Anti-
LMP2 (top), polyclonal anti-NDV (bottom panel) were used to detect respective proteins. Anti-gB: un-transfected CHO cells, and purified 
gp350/220 VLPs, were neg. controls; CHO cells transfected with gB-WT or gB-NDV-F chimera, gB-His-tagged were pos. controls. (G) 
Purity of the gB-LMP2 VLPs were analyzed by silver stain, VLP component proteins of predicted sizes were detected as indicated; NDV 
was pos. control, BSA was used for quantification.
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EBV generated the highest titer of IgG-specific antibodies, 
whether we used transfected ELL-0 cells or soluble gp350 
purified from HEK-293 cells (Immune Tech).
To assess the ability of VLP-immunized sera to 
neutralize infection in vitro, we quantitated sera collected 
at Days 14, 18, 33, 46, 68, and 97. (Figure 5A) Infection 
of HEK-293 or Raji cells with purified AGS-EBV-eGFP 
was used to conduct neutralization using pooled sera from 
Day 97 sera. HEK-293 and Raji cell lines are susceptible 
to EBV infection, and represent both epithelial and B 
cell lineages. The virus titer was determined as described 
[20]. The percent of eGFP+ cells was determined by flow 
Figure 4: Immunization and generation of EBV-specific IgG antibodies in immunized BALB/c mice. A. Immunization 
and bleeding schedule of 6–8-week-old female BALB/c mice. A total of 9 groups of BALB/c were immunized with 10 mg of purified 
gp350/220, gB-LMP2, gH/gL-EBNA1 VLPs or a combination of gp350/220 and gB-LMP2; gp350/220 and gH/gL-EBNA1; gB-LMP2 and 
gH/gL-EBNA1; or gp350/220, gH/gL-EBNA1, and gB-LMP2 VLPs. Two groups were also immunized with purified UV-inactivated EBV 
(10 mg) and TNE buffer, as positive and negative controls, respectively. B. EBV-glycoprotein IgG specific Ab titer in sera from immunized 
BALB/c mice was determined using lysate from lytically induced AGS-Akata cells as target, and detected by ELISA at Days 14, 18, 33, 46, 
68, and 97 for each individual mouse. ELISA assay was repeated at least three times. Results are expressed as mean ± standard deviations 
(SD).
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cytometry as previously described [20]. Purified antibody 
known to block EBV infection (anti-gp350/220 [72A1]) 
[55, 56] served as a positive control (data not shown). 
Effective neutralization titer was defined as 50% inhibition 
of infection, compared to control serum samples from 
EBV-seronegative animals.
When 5µl of AGS-EBV-eGFP virus was pre-
incubated with a serial dilution (1:2.5, 1:5, and 1:10) 
of sera from TNE-immunized mice (negative control), 
fluorescence dropped from 19.1% (virus alone) to 10% 
in HEK-293 cell line. Similar results were observed in 
Raji cells. In contrast, when AGS-EBV-eGFP was pre-
incubated with serially diluted sera from mice immunized 
with gH/gL-EBNA1 VLPs, gB-LMP2 VLPs, gp350/220 
VLPs, or UV-inactivated EBV, infection was reduced in 
a dose-dependent manner compared to TNE-immunized 
sera (Figure 5B–5C). Purified anti-gp350/220 mAb 72A1 
(5 µg/ml) (positive control) was the most effective in 
neutralizing EBV infection, reducing infection by >70% 
in both Raji and HEK-293 cells. In our hands, at 1:2.5 
dilution, sera from mice immunized with UV-inactivated 
EBV significantly neutralized EBV infection of Raji cells 
compared to sera from mice immunized with gp350/220 
(p = <0.0001), gB-LMP2 (p = <0.0001) or gH/gL-
EBNA1 (p = <0.0001) VLPs (Figure 5B). Between the 
VLPs, sera from mice immunized with gH/gL-EBNA1 
VLPs significantly reduced EBV infection of Raji cells 
compared to sera from mice immunized with gp350/220 
(p = 0.0374) or gB-LMP2 (p = 0.0112) VLPs. There was 
no significant difference in virus neutralization between 
sera from mice immunized with gp350/220 and gB-LMP2 
VLPs. Similar trends were observed at 1:5 dilution and 
at the highest dilution (1:10). At 1:10 dilution, sera from 
UV-inactivated EBV mice was superior to gp350/220 (p 
= 0.0021) VLPs. However, no significant difference was 
observed between UV-EBV and either gH/gL-EBNA1 
or gB-LMP2 VLP at this dilution. Between the VLPs, 
similar to the 1:2.5 dilution, serum diluted 1:10 from gH/
gL-EBNA1 was superior to gp350/220 (p = 0.0029), but 
not gB-LMP2. However, at this dilution, sera from mice 
immunized with gB-LMP2 VLPs neutralized better than 
sera from gp350/220 VLPs (p = 0.026).
When we performed the neutralization assay in 
HEK-293 epithelial cells, sera from mice immunized 
with UV-inactivated EBV at the 1:2.5 dilution effectively 
neutralized 94.3% of EBV infection, followed by sera 
from mice immunized with gH/gL-EBNA1 VLPs 
(77.9%), gB-LMP2 VLPs (76.8%), and gp350/220 VLPs 
(54.9%) (Figure 5C). Overall, our experiments confirmed 
that sera from mice immunized with gH/gL-EBNA1 or 
gB-LMP2 VLPs neutralized EBV infection in vitro better 
than gp350/220 VLPs in both Raji and HEK-293 cells.
Figure 5: Antibody titer and percent EBV neutralization. A. The absorbance resulting from serum antibody binding to plates 
coated with lysate from lytically induced AGS infected with EBV-Akata strain is shown for each vaccination group for individual mice. 
Absorbance data are shown as the mean ± the SEM for five mice from three independent ELISAs. Data points represent individual mice. 
B-C. Pooled sera from terminal bleed (Day 97) from 5 animals/immunization treatment were pre-incubated with eGFP-EBV in 1:2.5, 1:5 
or 1:10 dilution) as shown in the bar graphs for each immunogen, then incubated at 37°C for 48 h with Raji cells (B) or HEK-293 cells (C) 
seeded in total volume of 100µl of serum free media; EBV-EGFP+ cells were enumerated by flow cytometry. Neutralizing anti-gp350/220 
mAb (72A1; dashed line) served as positive control and neutralized >70% of the EBV infection in Raji cells and 100% in HEK 293 cells 
(data not shown). TNE served as negative control and was used to normalize percent infection. The neutralization assays were repeated 
three times in Raji cells and twice in HEK-293 cells. Results are expressed as mean ± standard deviation (SD) for Raji cells. Horizontal 
black lines terminating in short vertical lines compare sets of neutralization experiments with 2-sided p-values <0.05.
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Surprisingly, sera from mice immunized with a 
combination of two VLPs (gH/gL-EBNA1 and gB-
LMP2, gH/gL-EBNA1 and gp350/220, or gB-LMP2 
and gp350/220), or with all three VLPs, did not 
significantly reduce EBV infection compared to the 
single glycoprotein immunogens, in either of the cell 
lines used. In fact, pre-incubation of EBV with sera 
from mice immunized with both gB-LMP2 and gH/
gL EBNA1 somewhat increased infection of HEK-293 
cells.
To quantitate T-cell activation in immunized mice, 
we stimulated splenocytes (5x105) from sacrificed mice 
in vitro with 1 μg/mL synthetic peptide antigens derived 
from EBNA1
(HPVGEADYFEY),
 LMP2
(CLGGLLTMV)
, or Promix 
EBV-peptide pool (PeproTech). After overnight culturing, 
we used ELISA to test supernatants for release of IFN-γ, 
an indicator of T-cell activation. Splenocytes from mice 
immunized with gH/gL-EBNA1 VLPs or gB-LMP2 
VLPs generated significantly higher IFN-γ in response to 
EBNA1 (Figure 6A) or LMP2 (Figure 6B) peptides than 
Figure 6: In vitro activation of T cells isolated from BALB/c mice immunized with gH/gL-EBNA1, gB-LMP2, or 
gp350/220 VLPs. A group of five BALB/c mice per treatment were immunized with 10 μg of gH/gL-EBNA1, gp350/220, and gB-LMP2 
VLPs and boosted twice at Days 29 and 54 without adjuvants. UV-inactivated EBV and TNE served as positive and negative controls, 
respectively. At day 97 mice were sacrificed, red blood cells lysed and 5×105 splenocytes from sacrificed mice were assessed for their 
response to in vitro stimulation with 1 μg/mL of synthetic peptides derived from EBNA1
(HPVGEADYFEY)
, LMP2
(CLGGLLTMV)
, or Promix EBV 
peptide pool. After overnight culturing, the supernatants were tested for IFN-γ release by ELISA. Splenocytes from mice immunized 
with gH/gL-EBNA1 VLPs or gB-LMP2 VLPs generated significantly higher IFN-γ than mice immunized with UV-inactivated EBV and 
gp350/220 VLPs. SIINFEKL ovalbumin was used as a negative control. The experiment was replicated three times. Results are expressed 
as mean ± standard deviations (SD).
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mice immunized with UV-inactivated EBV or gp350/220 
VLPs, relative to mice immunized with TNE buffer 
alone (negative control). Stimulation with a pool of EBV 
peptides gave similar results (Figure 6C). SIINFEKL 
ovalbumin was used as a negative control (Figure 6D) and 
concavalin A and IL1β were used as model antigens (data 
not shown). These results confirm that gH/gL-EBNA1 
and gB-LMP2 VLPs can stimulate EBV-specific T-cell-
mediated immune response in vivo.
DISCUSSION
We have developed a novel platform for generating 
polyvalent EB VLPs that are produced in CHO cells and 
incorporate and package both EBV surface glycoproteins 
and intracellular proteins. Combined expression of surface 
glycoprotein(s) known to mediate viral entry (gp350/220, 
gH/gL, or gB), and proteins important for establishment of 
viral latency (EBNA1 or LMP2), allowed us to generate 
unique VLPs that can serve as polyvalent prophylactic and 
therapeutic EBV vaccine candidates. To our knowledge, 
the incorporation of select EBV surface glycoproteins 
and packaging of viral T-cell antigens inside the VLPs is 
unique to our study; we consider it a critical advancement 
in the development of a safe and effective polyvalent EBV 
vaccine, compared to previously reported candidates [13, 
20, 42]. Importantly, our vaccine candidates induced nAbs 
and also generated EBNA1- or LMP2-specific T cells 
in immunized wild-type BALB/c mice. Thus, we have 
established that generating a polyvalent prophylactic and 
therapeutic vaccine against EBV is feasible.
Because of gp350/220’s critical role as the 
attachment protein in viral entry, and observations that 
mAb directed against the protein (72A1) blocks EBV 
infection in vitro [56], to date all efforts to develop 
prophylactic EBV vaccines have primarily focused on 
this protein, with variable success [2, 11, 52]. However, 
our data shows pooled serum from mice immunized 
three times with gH/gL-EBNA1, without any adjuvant, 
neutralized EBV infection more effectively than pooled 
sera from mice immunized with gp350/220 VLPs, in 
both B cells and epithelial cells. The importance of 
these alternate glycoproteins is supported by other 
evidence, including that recombinant EBV lacking gH 
does not infect either epithelial or primary B cells [57]. 
Although antibodies to gH/gL are not robustly produced 
in vivo during natural infection (perhaps due to masking 
by the immunodominant gp350/220), immunization 
of animals with recombinant gH or gH/gL can boost 
immunogenicity and generate antibodies capable of 
blocking EBV infection [28, 53, 58, 59]. The ability of gH/
gL antibodies to neutralize infection is also well-conserved 
in herpes simplex virus-1 [60, 61], cytomegalovirus [62], 
and Kaposi sarcoma herpesvirus [63]. Furthermore, 
monoclonal antibodies to the gH protein or the gH/gL 
complex block EBV infection, supporting a critical role 
for gH/gL in EBV infection [30, 64].
Importantly, a recent report that rabbits immunized 
with 25 µg of gH/gL or gB, and enhanced with 
aluminum hydroxide as an adjuvant, generated superior 
nAb responses (100-fold and 20-fold, respectively) 
to gp350/220 supports our findings [53]. Although no 
specific nAbs to EBV gL or gB have been reported in 
patients to date [11], gB-specific nAbs have been tested in 
several clinical trials to prevent neonatal cytomegalovirus 
infection [65-67]. In our study, pooled sera from mice 
immunized with UV-inactivated EBV still had the best 
neutralization effect in epithelial and B-cell lines, which 
suggests that an effective EBV prophylactic vaccine may 
require inclusion of more than two glycoproteins, since 
the EBV entry mechanism involves multiple surface 
glycoproteins.
Surprisingly, sera from mice immunized with a 
mixture of both gH/gL-EBNA1 and gB-LMP2 VLPs had 
a contrasting outcome: supporting rather than blocking 
infection of epithelial cells. Whether this is true in 
natural infection, or whether co-expression of the three 
glycoproteins together on the surface of a single VLP 
(since gB, gH, and gL form a heteromeric complex) will 
have a different outcome remains to be explored. Pooled 
sera from mice immunized with both gp350/220 and 
gB-LMP2 VLPs or with gB-LMP2, gp350/220, and gH/
gL-EBNA1 VLPs did not provide a better neutralization 
outcome than the use of single immunogens in both cell 
lines tested. Only pooled sera from mice immunized with 
both gp350/220 and gH/gL-EBNA1 VLPs achieved an 
additive effect in the HEK-293 cell line, suggesting that a 
strategy combining these two immunogens might achieve 
sterile immunity, particularly if it is enhanced by the use of 
adjuvants, as for the case of three FDA-approved human 
papillomavirus vaccines.
In summary, our study demonstrates that EB VLPs 
can be stably produced in CHO cells, which grow to 
high density in suspension [68]. CHO cells can also be 
grown without FBS, allowing for more efficient and cost-
effective preparation, and setting the stage for large-scale 
production. This is yet another benefit to the production of 
VLPs in the CHO cell line, an FDA-approved vehicle for 
production of almost all currently licensed biologics, and 
is a significant step toward producing a safe EBV vaccine. 
The appearance of adventitious viral products, a typical 
artifact of production in cell lines of human origin, and 
a major concern to regulatory authorities, has not been 
reported for CHO cells [69]. These VLPs were found to 
be immungenic by generating nAbs and EBV-specific 
T-cell responses in immunized mice, suggesting they are 
a potentially safe and effective EBV polyvalent vaccine.
In future studies, we aim to improve our current 
vaccines by generating a polyvalent vaccine candidate that 
combines gp350/220-gH/gL-EBNA1-LMP2 as a single 
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VLP. It might also be important to consider including 
gp42 as part of the proposed pentameric VLPs, as nAbs 
to gp42 have been detected in human sera [54], and 
interaction between gp42/gH/gL is known to mediate viral 
infection in B cells [34]. We will also explore whether use 
of adjuvants will improve immunogenicity to achieve 
optimal neutralization. Testing these vaccines in recently 
developed humanized mouse-disease models (e.g., Burkitt 
lymphoma, PTLD) [70-73] will help inform whether the 
candidate vaccine can serve as an alternative to adoptive 
immunotherapy or as a cancer immunotherapy agent 
against EBV-associated cancers.
MATERIALS AND METHODS
Virus and Cell lines
The B95-8 cell line (marmoset B cell line) harboring 
recombinant Epstein-Barr virus (EBV) expressing an 
enhanced green fluorescence protein (eGFP) reporter at 
the LMP2A locus (B95-8-eGFP) [74] was a generous gift 
of Dr. R. Longnecker (Northwestern University, Chicago). 
The AGS cell line (human gastric adenocarcinoma cell 
line) infected with a recombinant Akata EBV expressing 
eGFP at the thymidine kinase locus (AGS-EBV-eGFP) 
[75, 76] was a generous gift of Dr. L. Selin (University of 
Massachusetts Medical School).
HEK-293 (human embryonic kidney), Raji (EBV-
positive Burkitt lymphoma), CHO, ELL-0 (chicken 
embryo), and HB168 (72A1 murine hybridoma) cell 
lines were all purchased from the American Type Culture 
Collection. B95-8-eGFP, Raji, and HB168 cells were 
cultured in RPMI media. HEK-293, CHO, and ELL-
0 cells were cultured in Dulbecco’s Modified Eagle’s 
medium (DMEM). AGS-EBV-eGFP cells were cultured 
in Ham’s F-12 media. Both B95-8-eGFP and AGS-
EBV-eGFP media were supplemented with 50µg/ml of 
neomycin (G418). All media contained 1% L-glutamine, 
10% heat-inactivated fetal bovine serum (FBS), and 2% 
penicillin-streptomycin unless otherwise specified. Lytic 
induction and purification of virus from B95-8-eGFP and 
AGS-EBV-eGFP cell lines harboring EBV-eGFP was 
performed as described [77]. Purified B95-8-eGFP and 
AGS-EBV-eGFP viruses were titered in both HEK-293 
and Raji and HEK-293 cells and stocks kept in -80°C for 
subsequent experiments.
Antibodies
Primary antibodies: Mouse monoclonal 72A1 (anti-
gp350/220) was purified from HB168, a producer cell 
line, as described [56]. Rabbit polyclonal anti-Newcastle 
disease virus (NDV) has been described [78] and was a gift 
of Dr. T. Morrison, University of Massachusetts Medical 
School, Worcester, MA. Rat monoclonal anti-EBV nuclear 
antigen 1 (EBNA1; IH4-1) was a gift of Dr. F. Grässer, 
Institut für Virologie, Germany [79]. Goat polyclonal 
anti-EBNA1 (Gly-Arg regions) and rat monoclonal 
anti-EBV latent membrane protein 2 (LMP2A; 14B7) 
were purchased from Abcam. Mouse monoclonal anti-
eGFP (GSN149) was purchased from Sigma. Anti-gH/
gL (E1D1, CL40) and anti-gB (CL55, N-terminal; BA23, 
C-terminal) were gifts of Dr. L. Hutt-Fletcher (Louisiana 
State University Health Sciences Center, Shreveport, LA); 
mouse monoclonal E1D1 recognizes the gH/gL complex 
and partially blocks integrin binding, likely on the domain 
I/domain II interface [80]; mouse monoclonal CL40 
recognizes the gH/gL complex; mouse monoclonal CL55 
recognizes the gB ectodomain; rabbit polyclonal BA23 
recognizes the gB C-terminal domain.
Secondary antibodies: Horseradish peroxidase 
(HRP)-conjugated goat anti-mouse IgG (total and isotype 
specific), goat anti-rabbit, goat anti-rat, or rabbit anti-goat 
antibodies for immunoblot or ELISA were purchased from 
Bio-Rad. Alexa Fluor (AF) 488- or AF594-conjugated 
goat F(ab’)2anti-mouse IgG (H+L) for flow cytometric 
analyses or confocal microscopy were purchased from 
Life Sciences Tech.
Plasmid vectors
Construction of pCI-puro has been previously 
described [26]. All other cDNA sequences were 
synthesized by Genewiz, South Plainfield, NJ, cloned 
into the pCAGGS mammalian expression vector [81], and 
fidelity was verified by sequencing the cDNAs. All cDNA 
sequences encoding EBV surface glycoproteins and latent 
membrane proteins were derived from B95-8 virus [82]. 
VLP component plasmids pCAGGS-fusion (F), pCAGGS-
hemagglutinin-neuraminidase (HN), pCAGGS-matrix 
(M), and pCAGGS-nucleocapsid protein (NP) derived 
from NDV (Avulavirus) have been described [83].
pCAGGS-gp350/220-F
Full-length EBV gp350/220 (BLLF1) from the 
BamHI L fragment of EBV genome strain B95-8 [82] 
was amplified by PCR as previously described [20]. 
To construct the gp350/220-F chimera, the gp350/220 
ectodomain (amino acids (aa) 1-864) was fused to the 
NDV F transmembrane (TM) and cytoplasmic (CT) 
domains (aa 499-553).
pCAGGS-gH-F, pCAGGS-gL-HN, and pCAGGS-gB-F
The rationale for fusion of type 1 membrane protein 
to NDV F protein and type 2 membrane protein to NDV 
HN has been described [19]. Chimeras were constructed 
as follows: gH-F chimera, NDV F TM/CT domains (aa 
499-553) were fused to the ectodomain (aa 1-679) of 
EBV gH (gp85; type 1); gL-HN chimera, NDV HN TM/
CT domains (aa 1-45) were fused to the ectodomain 
(aa 25-137) of EBV gL (gp25; type 2); gB-F chimera, 
NDV F TM/CT domains (aa 499-553) were fused to the 
ectodomain (aa 1-736) of EBV gB (gp110; type 1).
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pCAGGS-eGFP-NP, pCAGGS-EBNA1-NP, and 
pCAGGS-LMP2-NP
Full-length NDV-NP (aa 1-489) was synthesized 
and fused to a 29-aa (PATLSLPPDHPNSSARSPPP 
DPGAAGAGA) linker sequence [84]. To construct 
the chimeras, NDV NP-GAAGAGA was fused to the 
following components: eGFP-NP chimera, eGFP (amino 
acids 1-241); EBNA1-NP chimera, truncated EBV 
EBNA1 (aa 326-641; the truncated sequence lacks the 
Gly-Ala regions known to impair presentation of cis-
linked sequences to MHC class I); LMP2-NP chimera, 
full-length EBV LMP2 (aa 1-497).
Control plasmids
cDNA sequences of genes encoding full-length: 
gp350/220 (aa 1-907), gH (aa 1-707), gL (aa 1-137), gB 
(aa 1-790), gB-His (aa 1-742), eGFP (aa 1-241), EBNA1 
(aa 1-641), and LMP2 (aa 1-497 were individually cloned 
into pCAGGS for use as experimental controls.
Transfection
1.0 µg/well of empty pCAGGS, and pCAGGS 
vectors containing full-length gp350/220, gp350/220-F, 
full-length gH, gH-F, full-length gL, gL-HN, full-
length gB, gB-F, full-length eGFP, eGFP-NP, full-
length EBNA1, EBNA1-NP, full-length LMP2, and 
LMP2-NP were individually transfected into 80% 
subconfluent CHO cells seeded in six-well tissue 
culture plates using Lipofectamine and Reagent Plus 
(Life Sciences Technologies) following manufacturer’s 
recommendations. To assess formation of the gH/
gL complex, pCAGGS-gH-F and pCAGGS-gL-HN 
or pCAGGS-gH and pCAGGS-gL plasmids were co-
transfected in combination into CHO cells.
VLP assembly and production
For VLP preparation, equal amounts (8 µg/
plasmid) of the relevant plasmids were co-transfected 
into 80% confluent CHO cells seeded in T-175cm2 flasks; 
supernatant from transfected cells was collected and VLPs 
were purified as previously described [18, 20]. VLPs were 
constructed using co-transfection of relevant pCAGGS 
plasmids as follows: gp350/220-F VLP – gp350/220-F, 
NDV-NP, and M; gp350/220-eGFP VLP – gp350/220-F, 
eGFP-NP, M, and pCIpuro; gp350/220-EBNA1 VLP – 
gp350/220-F, EBNA1-NP, and M; gH/gL-EBNA1 VLP 
– gH-F, gL-HN, EBNA1-NP, and M; and gB-LMP2 VLP 
– gB-F, LMP2-NP, and M.
Imaging eGFP-positive cells
Cells transfected with plasmids expressing eGFP 
(pCAGGS-eGFP, pCAGGS-eGFP-NP) or untransfected 
CHO cells (negative control) were imaged using filters 
set for FITC, with an excitation wavelength of 488 nm 
resulting in emission at 507 nm, as described [77].
Generation of stable CHO cells producing 
gp350/220-eGFP VLPs
To generate a stable CHO cell line producing 
gp350/220-eGFP VLPs, 1.0 µg/well of pCAGGS-
gp350/220-F, pCAGGS-eGFP-NP, pCAGGS-M, and 
pCIpuro plasmids were co-transfected into 1x105 CHO 
cells seeded in a six-well tissue culture plate. At 48 hours 
post-transfection, 10 µg/ml of puromycin was used to 
select transfected cells. Individual colonies were cloned 
and expanded, followed by flow cytometric sorting using 
anti-gp350/220 antibody (mAb 72A1) and eGFP. Cells 
were seeded and passaged 10 times and VLP production 
was assessed in each passage by immunoblot as described 
below.
Flow cytometry, silver stain, and immunoblot 
detection of proteins
To assess surface expression of relevant protein(s) 
and protein complexes by flow cytometry, transfected cells 
were harvested at 48 hours post-transfection and stained 
with relevant primary and secondary antibodies. Flow 
cytometric analysis was performed on an LSRII benchtop 
FC (Becton-Dickinson, B-D) and data was analyzed using 
CellQuest Pro Version 4.0.1 (BD Biosciences) and/or 
FlowJo Cytometry Analysis software (FlowJo, LLC) as 
described [20]. All the experiments were independently 
repeated at least three times unless otherwise specified.
To assess expression of relevant protein(s) and 
protein complexes using silver stain and immunoblot, 
purified VLPs, NDV, and B95-8-eGFP, untransfected 
CHO cells (negative control), or cells transfected with 
various pCAGGS plasmids were lysed in RIPA buffer 
(Boston Bioproducts) containing complete protease 
inhibitor cocktail (Roche Applied Science). Lysates 
were incubated on ice for 30 min, and then centrifuged 
for 5 min at 18,407 rcf in a microcentrifuge. The protein 
content of the lysates was determined by Bradford assay 
using Coomassie Brilliant Blue (Sigma). Lysates were 
boiled for 5 min in Laemmli SDS sample buffer (Boston 
Bioproducts) under non-reducing or reducing conditions. 
A known quantity of protein lysate was separated on a 
4–12% gradient polyacrylamide gel. Pierce silver stain 
kit (Thermo-Fisher) was used to detect proteins following 
manufacturer’s recommendations. All the experiments 
were independently repeated at least three times unless 
otherwise specified. Immunoblot analyses were performed 
by transferring proteins from the gel to a PVDF membrane 
using iblot (Thermo-Fisher). Membranes were pre-
incubated with 5% non-fat dry milk (LabScientific) for 
30 min and detected with relevant primary and secondary 
antibodies as previously described [26, 85].
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Immunization of BALB/c mice
Nine groups (n=5/treatment) of 8–10-week-old 
female BALB/c mice were immunized intraperitoneally 
three times (Day 0, 29, 54) with 10 μg of purified 
gp350/220-F, gH/gL-EBNA1, or gB-LMP2 VLPs, or 
with a combination of 10 μg of each of two or three of 
the VLPs, in 0.5 ml of TNE buffer (100 mM Tris; 2.0 M 
NaCl; 10 mM EDTA; ~10% sucrose; pH 7.4). Purified 
UV-inactivated EBV (B95-8-eGFP) and gp350/220-F 
VLPs served as positive controls; TNE buffer alone served 
as negative control. To assess the short, mid, and long-
term immunogenic nAb responses, mice were tail vein-
bled to obtain serum at two and four weeks after primary 
immunization and again once after both secondary (Day 
29) and tertiary (Day 54) boost immunizations. On Day 
97, mice were sacrificed and terminal bleed (~1 mL) was 
collected for use in determination of antibody titer and 
EBV neutralization assays. Splenocytes were collected 
from sacrificed mice for determination of EBNA1- and 
LMP2-specific T-cell responses as described [86].
Determination of antibody titer by ELISA
To assess the EBV IgG-specific antibody titer for 
each immunized mouse, enzyme linked immunosorbent 
assay (ELISA) was performed as previously described 
[87] using various target antigens. Target antigens 
comprised: lysates from induced AGS-EBV-eGFP cells; 
lysates from ELL-0 cells transfected with pCAGGS 
plasmids containing full-length gp350/220, or soluble 
gp350 ectodomain (aa 4-863) proteins (Immune 
Technology Corp). Briefly, 4 µg of pCAGGS plasmids 
expressing relevant surface glycoproteins were transfected 
into ELL-0 cells seeded in T-75 cm2 flasks. Triton X lysis 
buffer was used to extract lysates from induced AGS-
EBV-eGFP cells or transfected ELL-0 cells (48 hours post-
transfection). Dilutions of the cell extracts were adjusted 
so that the amount of glycoprotein targets was comparable 
from experiment to experiment, as determined by Western 
blotting and Bradford assay. Untransfected ELL-0 or 
uninduced AGS-EBV-eGFP cell extracts served as 
negative controls. ELL-0 cells provided less non-specific 
background in the ELISA assay.
To perform ELISA, 96-well microtiter plates 
(Nunc-Immuno Plate with Maxisorp surface treatment) 
were coated with 50 µl/well of lysates expressing 
relevant viral glycoproteins (1 µg/ml) in a phosphate-
buffered saline (pH 7.2) overnight at 4oC. After blocking 
the plates with 2% bovine serum albumin (BSA), serial 
dilutions (in PBS) of sera from Days 14, 18, 33, 46, 68, 
and 97 (terminal bleed) were bound for 2 hours at room 
temperature. Antibody binding was detected using HRP-
conjugated goat anti-mouse IgG secondary antibody at 
room temperature for 1 hour. The plates were washed five 
times with PBS and the chromogenic substrate 2,2’-azino-
bis(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS, 
Life Science Technologies) was added. The reaction 
was stopped using ABTS Peroxidase Stop Solution 
containing 5% sodium dodecyl sulfate (SDS) in water. 
To determine the antibody titer, optical density was read 
at 405nm (OD
405
) with ELISA reader (Spectramax® Plus 
384, Molecular Devices). The highest dilution yielding 
an OD
405
 two times higher than that of TNE-treated mice 
without dilution was designated as the antibody endpoint 
titer. Anti-gp350/220 (mAb 72A1) was used as a standard 
for the ELISA assays. Three independent replicates of the 
experiments were performed at least three times.
EBV neutralization assays
Pooled sera from Day 97 (terminal bleed) of mice 
immunized with gp350/220-F, gH/gL-EBNA1, or gB-
LMP2 VLPs, or with a combination of 10 μg of each of 
two or three of the VLPs, UV-inactivated EBV, or TNE 
buffer alone were complement heat-inactivated at 56°C 
and diluted in RPMI without FBS. Sera were diluted by 
1:2.5, 1:5, and 1:10 and incubated with 5µl of purified 
AGS-EBV-eGFP (titer calculated to infect at least 20% of 
HEK-293 cells seeded in 100µl of serum-free DMEM) for 
1 hour at room temperature. To represent EBV infection 
of B and epithelial cells, AGS-EBV-eGFP-incubated with 
sera from immunized mice were used to infect 1x105 Raji 
or 5x104 HEK-293 cells, respectively, seeded in a 48-well 
plate. Anti-gp350/220 (72A1 nAb), and serum from TNE 
only-treated mice served as positive and negative controls, 
respectively. Plates were incubated at 37°C and the 
number of GFP+ cells was determined by flow cytometry 
48 hours post-infection. All dilutions were performed in 
triplicate and the assays repeated at least two times for 
Raji cells. Due to sera limitation, neutralization in HEK-
293 cells was performed only twice, that is why statistical 
analysis was performed in Raji cells.
Determination of EBNA1- and LMP2-specific 
T-cell responses in BALB/c immunized mice
To quantitate T-cell activation in immunized mice, 
splenocytes (5x105) from sacrificed immunized mice 
were stimulated in vitro with 1 μg/mL synthetic peptides 
derived from EBNA1
(HPVGEADYFEY)
, LMP2
(CLGGLLTMV)
, or 
Promix EBV-peptide pool (PeproTech). After overnight 
culturing at 37°C, supernatants were tested for IFN-γ 
release, an indicator of T-cell activation, by ELISA, as 
described above. SIINFEKL ovalbumin was used as a 
negative control and concavalin A and IL1β were used as 
model antigens [88]. All experiments were replicated three 
times.
Statistical analysis
Graph Pad Prism 6 Software was used for statistical 
analyses of data. The differences between the nAb titers 
or EBNA1- and LMP2-specific T-cell responses of the 
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immunized and non-immunized group (TNE-treated) of 
mice were analyzed using unpaired two-tailed t-tests for 
independent groups. Statistical significance of the tests 
was based on a p-value equal to or lower than 0.05.
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